Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2005 Jul 8;6(1):68.
doi: 10.1186/1465-9921-6-68.

Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients

Affiliations
Controlled Clinical Trial

Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients

Daniel Droemann et al. Respir Res. .

Abstract

Background: Cigarette smoke exposure including biologically active lipopolysaccharide (LPS) in the particulate phase of cigarette smoke induces activation of alveolar macrophages (AM) and alveolar epithelial cells leading to production of inflammatory mediators. This represents a crucial mechanism in the pathogenesis of chronic obstructive pulmonary disease (COPD). Respiratory pathogens are a major cause of exacerbations leading to recurrent cycles of injury and repair. The interaction between pathogen-associated molecular patterns and the host is mediated by pattern recognition receptors (PRR's). In the present study we characterized the expression of Toll-like receptor (TLR)- 2, TLR4 and CD14 on human AM compared to autologous monocytes obtained from patients with COPD, healthy smokers and non-smokers.

Methods: The study population consisted of 14 COPD patients without evidence for acute exacerbation, 10 healthy smokers and 17 healthy non-smokers stratified according to age. The expression of TLR2, TLR4 and CD14 surface molecules on human AM compared to autologous monocytes was assessed ex vivo using FACS analysis. In situ hybridization was performed on bronchoalveolar lavage (BAL) cells by application of the new developed HOPE-fixative.

Results: The expression of TLR2, TLR4 and CD14 on AM from COPD patients, smokers and non-smokers was reduced as compared to autologous monocytes. Comparing AM we detected a reduced expression of TLR2 in COPD patients and smokers. In addition TLR2 mRNA and protein expression was increased after LPS stimulation on non-smokers AM in contrast to smokers and COPD patients.

Conclusion: Our data suggest a smoke related change in the phenotype of AM's and the cellular response to microbial stimulation which may be associated with impairment of host defenses in the lower respiratory tract.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Flow cytometry expression of CD14, TLR4 and TLR2 on monocytes and autologous alveolar macrophages (AM). rMFI (± SD) is shown from non-smokers (n = 10). White bars = monocytes, black bars = AM. * = p < 0.01 vs. AM. rMFI = relative mean fluorescence intensity. (B) Representative histogram from experiments with monocytes.
Figure 2
Figure 2
(A) Flow cytometry expression of TLR2 and TLR4 on alveolar macrophages (AM). rMFI (± SD) is shown from non-smokers (white bars [young], n = 10, horizontal hatched bars [elderly], n = 7), smokers (diagonal hatched bars, n = 10) and COPD patients (black bars, n = 14). * = p < 0.01 vs. smokers and COPD patients AM. rMFI = relative mean fluorescence intensity. (B) Representative histogram from experiments with AM.
Figure 3
Figure 3
LPS-stimulation of TLR2 protein and mRNA on alveolar macrophages (AM). (A) Flow cytometry expression. rMFI (± SD) is shown from non-smokers (young n = 10, elderly n = 7), smokers (n = 10) and COPD patients (n = 14). rMFI = relative mean fluorescence intensity. * = p < 0,04. In situ hybridization targeting TLR2 mRNA of HOPE-fixated BAL cells. Cells from non-smokers before (B) and after (C [young], D [elderly]) LPS-stimulation. Cells from COPD patients (E) after LPS-stimulation (Anti-DIG-AP-New-fuchsine; 600x).

References

    1. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest. 2000;118:1557–1565. doi: 10.1378/chest.118.6.1557. - DOI - PubMed
    1. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852. doi: 10.1136/thorax.57.10.847. - DOI - PMC - PubMed
    1. Prieto A, Reyes E, Bernstein ED, Martinez B, Monserrat J, Izquierdo JL, Callol L, de Lucas P, Alvarez-Sala R, Alvarez-Sala JL, Villarrubia VG, Alvarez-Mon M. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferon) Am J Respir Crit Care Med. 2001;163:1578–1583. - PubMed
    1. White AJ, Gompertz S, Bayley DL, Hill SL, O'Brien C, Unsal I, Stockley RA. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax. 2003;58:680–685. doi: 10.1136/thorax.58.8.680. - DOI - PMC - PubMed
    1. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest. 1999;115:829–835. doi: 10.1378/chest.115.3.829. - DOI - PubMed

Publication types